Compare Boston Scientific Corporation (BSX) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Jumia Technologies AG - ADR — how do they compare? Boston Scientific Corporation trades at $42.73 (market cap $66.37B), while Jumia Technologies AG - ADR trades at $6.87 (market cap $848.39M). The key difference: Boston Scientific Corporation is far larger — about 78.2× Jumia Technologies AG - ADR's market cap, and Jumia Technologies AG - ADR is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | JMIA | |
|---|---|---|
Market Cap | $66.37B | $848.39M |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $14.60 |
52-Week Low | $42.63 | $4.45 |
Enterprise Value | $75.94B | $795.49M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
JMIA trades at $6.71, down 4.28% today, amid bearish technical signals despite analyst optimism. The company shows improving fundamentals with revenue growth to $189M in 2025 and narrowing losses, targeting 2027 profitability. Recent Q1 2026 results beat GMV guidance with 39% revenue growth, though EPS missed expectations. Cash flow turned positive in 2024-2025 after years of negative net flows.
Outlook remains speculative with high execution risk despite 71% analyst buy ratings. The path to profitability depends on successful African market expansion and cost management. Key risks include persistent losses, competitive pressures, and macroeconomic challenges in operating markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
